List of Excipients in Branded Drug NAFTIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merz Pharmaceuticals LLC	NAFTIN	naftifine hydrochloride	0259-4126	BENZYL ALCOHOL
Merz Pharmaceuticals LLC	NAFTIN	naftifine hydrochloride	0259-4126	CETYL ALCOHOL
Merz Pharmaceuticals LLC	NAFTIN	naftifine hydrochloride	0259-4126	CETYL ESTERS WAX

Last updated: August 3, 2026

ecutive summary: Naftin is a topical naftifine hydrochloride antifungal with limited remaining differentiation from the active ingredient itself. Commercial opportunities are concentrated in excipient-enabled delivery: improved cosmetic acceptability, faster drying, reduced irritation, better adherence, and dosage forms for intertriginous skin, feet, and potentially nails. The legacy 1% gel and 2% cream use conventional excipient systems, leaving room for differentiated generics, authorized-generic positioning, private-label products, and reformulated dermatology products. The principal risks are FDA product-specific bioequivalence requirements, limited ability to obtain broad composition-of-matter exclusivity, and possible classification of new delivery systems as 505(b)(2) products rather than simple ANDAs.

Naftin Excipient Strategy and Commercial Opportunities

What is Naftin and which formulations are commercially relevant?

Naftin contains naftifine hydrochloride, an allylamine antifungal used for topical treatment of dermatophyte infections. The marketed product has included 1% gel and 2% cream presentations. FDA labeling identifies naftifine hydrochloride as the active ingredient and describes the products as topical dermatological formulations for conditions such as tinea pedis, tinea cruris, and tinea corporis.[1,2]

Product attribute	Naftin 1% gel	Naftin 2% cream
Active ingredient	Naftifine hydrochloride	Naftifine hydrochloride
Strength	1%	2%
Route	Topical	Topical
Primary commercial use	Dermatophyte skin infections	Dermatophyte skin infections
Typical vehicle	Hydroalcoholic or polymeric gel	Oil-in-water cream
Key formulation objective	Fast drying and low residue	Emollience and skin coverage
Generic pathway	Product-specific ANDA requirements	Product-specific ANDA requirements
Biosimilar relevance	None	None

The two dosage forms address different patient preferences. Gel can be positioned for hairy areas, feet, and users who prefer rapid drying. Cream can be positioned for dry, fissured, or inflamed skin where emollience and occlusion may improve comfort.

What excipients are used in Naftin formulations?

Naftin 1% gel excipients

The Naftin 1% gel label identifies a conventional gel system that includes carbomer, disodium edetate, isopropyl alcohol, propylene glycol, purified water, and sodium hydroxide.[1] Each excipient has a functional role:

Excipient	Likely formulation function
Carbomer	Gel structure, viscosity, suspension stability
Isopropyl alcohol	Solvent, volatile vehicle, rapid drying
Propylene glycol	Cosolvent and humectant
Sodium hydroxide	Carbomer neutralization and pH adjustment
Disodium edetate	Chelation and potential stability support
Purified water	Continuous phase

This system is relatively simple and commercially reproducible. Its weaknesses are familiar to topical developers: alcohol-related stinging, tackiness from propylene glycol, drying of compromised skin, and potential viscosity changes caused by pH, electrolytes, or packaging interactions.

Naftin 2% cream excipients

The Naftin 2% cream label identifies benzyl alcohol, cetyl alcohol, cetyl esters wax, isopropyl myristate, polysorbate 60, sodium hydroxide, stearyl alcohol, and water.[2]

Excipient	Likely formulation function
Benzyl alcohol	Preservative and solvent
Cetyl alcohol	Consistency agent and emollient
Cetyl esters wax	Structural wax and texture modifier
Isopropyl myristate	Emollient and spreading agent
Polysorbate 60	Emulsifier
Sodium hydroxide	pH adjustment
Stearyl alcohol	Emulsion structure and viscosity
Purified water	Continuous phase

The cream vehicle provides a platform for texture, spreadability, and occlusivity improvements. Isopropyl myristate may improve skin feel and spreading but can create a greasy or oily perception depending on concentration and wax balance. Benzyl alcohol can create irritation or sensitization concerns in some users, creating a potential differentiator for preservative-reduced or alternative-preservative products.

What excipient strategies can improve Naftin products?

Can a low-irritation Naftin gel create commercial differentiation?

Yes. A low-irritation gel is one of the most accessible opportunities. The primary levers are:

• Reducing or replacing isopropyl alcohol.
• Rebalancing propylene glycol and other humectants.
• Using a less tacky polymer system.
• Controlling final pH near the skin-compatible range.
• Improving drying time without excessive solvent evaporation.
• Adding a film-forming polymer at a level that does not produce visible residue.

Candidate platforms include hydroxypropyl cellulose, hydroxyethyl cellulose, poloxamers, acrylates/C10-30 alkyl acrylate crosspolymers, and associative polyurethane polymers. Each option affects viscosity, drug release, skin retention, preservative demand, and manufacturing complexity.

The commercial objective should be a gel that spreads quickly, dries without whitening, and causes less sting on fissured skin. Claims must remain within the approved labeling unless supported through an appropriate FDA regulatory pathway.

Can a cream with improved skin feel compete with Naftin cream?

A cream can compete through sensory performance rather than a new active ingredient. Useful approaches include:

• Replacing part of the wax phase with lighter emollients.
• Reducing greasy after-feel.
• Improving rub-in and wash-off behavior.
• Using a lamellar emulsion for skin conditioning.
• Replacing benzyl alcohol where preservative performance allows.
• Developing a lower-water-activity system to support microbiological control.

Potential emollients include medium-chain triglycerides, C12-15 alkyl benzoate, diisopropyl adipate, isoamyl laurate, and selected silicone alternatives. These materials can alter naftifine solubilization, thermodynamic activity, release from the vehicle, and skin partitioning. A more elegant emollient system may improve adherence but can also reduce drug release if naftifine is overly comfortable in the vehicle.

What excipients are suitable for a preservative-reduced formulation?

A preservative-reduced product could have commercial value for patients with sensitive or damaged skin. The strategy requires control of microbial risk through the entire product system:

1. Low microbial burden in raw materials.
2. Validated manufacturing controls.
3. Low water activity or a robust antimicrobial system.
4. Airless or unit-dose packaging.
5. Container-closure integrity.
6. Preservative-effectiveness testing where applicable.

A preservative-free multidose cream is difficult to commercialize without packaging and microbiological controls that materially increase cost. Airless pumps, unit-dose sachets, and single-use applicators can reduce contamination risk but may raise packaging cost and complicate filling operations.

What formulations are protected by Naftin patents?

The original naftifine compound and early pharmaceutical patents are old and are unlikely to provide meaningful U.S. composition-of-matter exclusivity for current commercial development. The relevant protection question is formulation-specific: whether an active patent covers a particular vehicle, concentration, delivery system, or method of use.

The FDA Orange Book should be checked for current listed patents associated with the applicable Naftin NDA before relying on any freedom-to-operate conclusion.[3] FDA labeling and DailyMed materials establish the marketed formulation and approved use, but they do not replace a live patent search or claim chart.[1,2]

Potentially relevant patent categories include:

• Cream compositions containing naftifine hydrochloride.
• Gel compositions with specific polymer and solvent combinations.
• Enhanced penetration or skin-retention systems.
• Foams, sprays, films, and aerosol formulations.
• Combination products with keratolytics or anti-inflammatory agents.
• Methods for treating particular fungal infections.
• Packaging systems that preserve a low-preservative formulation.

A new excipient combination is not automatically patentable. Patent value is stronger where the formulation demonstrates an unexpected result, such as materially improved skin deposition, lower irritation, improved stability, or clinically relevant treatment adherence.

When does Naftin lose exclusivity?

Naftifine has been commercially available for decades, and the principal active-ingredient exclusivity period has expired. The current commercial barrier is therefore regulatory and technical execution rather than basic molecule exclusivity.

Exclusivity category	Naftin position
New chemical entity exclusivity	Expired
Composition-of-matter patent	Expected to be expired or commercially irrelevant
Orphan exclusivity	Not applicable to standard Naftin indications
Biologic exclusivity	Not applicable
Pediatric exclusivity	No central commercial significance identified
Formulation exclusivity	Must be assessed against current Orange Book listings
Method-of-use exclusivity	Must be assessed by indication and listed patent
Generic entry	Possible through FDA-approved topical pathways, subject to product-specific requirements

Topical generic approval can remain difficult even after basic patents expire. FDA may require evidence that the generic has equivalent active ingredient, strength, dosage form, route, quality attributes, and performance characteristics. For semisolid products, Q1/Q2 sameness, rheology, globule or particle attributes, drug release, and in vitro permeation may become important depending on the reference product and FDA guidance.[4]

What is the Orange Book status of Naftin?

The Orange Book is the controlling FDA source for listed patents and regulatory exclusivity associated with approved drug products.[3] Naftin’s Orange Book status must be reviewed by specific NDA, strength, and dosage form because cream and gel products may have different listings.

The practical diligence questions are:

• Which NDA corresponds to the current reference-listed product?
• Are any patents listed for the 1% gel?
• Are any patents listed for the 2% cream?
• Are listed patents active, expired, or subject to statutory disclaimers?
• Does the proposed generic match the reference product’s dosage form and strength?
• Is the intended product an ANDA, a 505(b)(2) application, or a cosmetic/OTC product outside the Naftin pathway?

A patent listing does not prove that a patent claim is valid or infringed. It determines the statutory certification framework for an ANDA applicant.

Which companies are challenging Naftin patents?

Naftin is an established topical product with no known biosimilar pathway. Generic competition would generally arise through ANDA applicants rather than biosimilar applicants. Paragraph IV risk depends on whether a patent is currently listed in the Orange Book for the relevant reference product.

An ANDA applicant could use:

• Paragraph I certification if no patent information is listed.
• Paragraph II certification if listed patents have expired.
• Paragraph III certification if the applicant waits until patent expiration.
• Paragraph IV certification if the applicant asserts that listed patents are invalid, unenforceable, or not infringed.

Any resulting litigation would be governed by the Hatch-Waxman framework and could trigger a 30-month stay under applicable conditions.[5] A complete list of active challengers requires a current Orange Book review and litigation-docket search. Publicly available product information does not establish a current, comprehensive list of Naftin challengers.

What generic launch risks exist for Naftin?

Simple generic cream or gel

A conventional generic can launch after satisfying ANDA requirements and resolving any listed-patent issues. The principal risks are:

• Failure to match the reference product’s critical quality attributes.
• Drug-release or in vitro permeation differences.
• Stability failure caused by naftifine precipitation.
• Preservative effectiveness failure.
• Packaging compatibility problems.
• Low reimbursement and intense topical-generic price competition.

Excipient-differentiated generic

A differentiated vehicle can support a premium or preferred-channel strategy, but it may increase regulatory risk. Changes to polymers, solvents, emulsifiers, or preservatives can change drug release and local exposure. A formulation that is clinically more elegant may not qualify as a straightforward substitutable generic if it departs materially from the reference product.

505(b)(2) reformulation

A foam, spray, film, nail delivery system, or combination product may be better suited to a 505(b)(2) application. This route can support reliance on FDA findings for naftifine while requiring new clinical, pharmacokinetic, local-tolerance, or performance data. The regulatory burden is higher, but so is the potential for differentiated pricing and a new patent estate.

What commercial opportunities exist for Naftin excipient innovation?

Fast-drying foot and athlete’s-foot products

A low-residue gel or spray could target consumers who dislike cream residue. The product could emphasize application convenience, drying time, and compatibility with socks or footwear. Packaging should support controlled dosing and minimize clogging from polymeric formulations.

Sensitive-skin cream

A cream with reduced fragrance, lower irritation potential, and improved barrier feel could target patients with fissured or inflamed skin. The commercial opportunity depends on demonstrating acceptable local tolerability and preserving naftifine release.

Hair-bearing-area delivery

A foam, mousse, or low-viscosity spray could improve application to the groin or other hair-bearing areas. Propellant selection, flammability, dose uniformity, and container compatibility become central development issues.

Nail and periungual delivery

Nail delivery is technically attractive but more difficult. Naftifine must cross the nail plate and reach the infected tissue. Film-forming systems, volatile solvents, penetration enhancers, and keratolytics may improve delivery, but the product may require new efficacy studies and a 505(b)(2) strategy. The commercial opportunity is larger than for a simple skin generic, but development risk is materially higher.

Combination products

Combinations with urea, salicylic acid, or other keratolytics may improve penetration or remove hyperkeratotic tissue. These combinations raise compatibility, irritation, labeling, and clinical-evidence issues. A combination product may have a stronger patent position if it produces an unexpected therapeutic result.

How strong is the Naftin patent estate?

The legacy Naftin estate is likely weak for broad molecule-based exclusivity because naftifine has been marketed for many years. The stronger opportunities are narrow, formulation-specific patents supported by comparative data.

Patent strategy	Commercial strength
Broad naftifine composition claim	Low
Conventional cream with routine excipients	Low
Conventional carbomer gel	Low to moderate
Low-irritation, alcohol-reduced gel with performance data	Moderate
Novel foam or film with demonstrated delivery benefit	Moderate to high
Nail-targeted delivery with clinical evidence	Moderate to high
Packaging-only claims	Moderate, usually narrow
Manufacturing process claims	Moderate if difficult to replicate

Patent drafting should focus on measurable formulation attributes rather than generic ingredient lists. Useful claim parameters may include viscosity ranges, pH, particle size, drug-release profiles, solvent ratios, water activity, preservative concentration, or skin-deposition results.

What manufacturing and geographic IP barriers apply?

Naftifine topical products are generally manufacturable with standard semisolid and gel equipment. The principal manufacturing barriers are process control and reproducibility:

• Carbomer hydration and neutralization.
• Uniform active incorporation.
• Prevention of drug crystallization.
• Emulsion droplet-size control.
• Deaeration and fill-weight consistency.
• Compatibility with pumps, tubes, and laminated packaging.
• Microbial control during filling and storage.

U.S. generic entry may be commercially unattractive if reimbursement falls rapidly. European, Canadian, Latin American, and Asian markets may have separate registration, trademark, formulation, and patent considerations. A product that qualifies as a generic in the United States may require different comparative evidence elsewhere, particularly where topical bioequivalence standards differ.

What licensing deals are relevant to Naftin?

The most logical licensing targets are not the old naftifine molecule. They are enabling technologies:

• Topical penetration systems.
• Low-irritation solvent systems.
• Airless packaging.
• Preservative-free multidose delivery.
• Foam and spray platforms.
• Nail-penetration technology.
• Dermatology contract manufacturers with approved topical facilities.

A licensing deal is more defensible where the technology can be reused across several antifungal or dermatology assets. A Naftin-only license may have limited value unless it includes regulatory history, validated manufacturing processes, clinical data, or a patent portfolio with remaining term.

What is the revenue exposure and competitive outlook?

Naftin competes with generic naftifine products, terbinafine, butenafine, clotrimazole, econazole, ciclopirox, and other topical antifungals. The market is generally price-sensitive, while brand value depends on physician prescribing, insurance coverage, patient adherence, and retail availability.

Revenue exposure is highest for a brand owner that relies on:

• Premium pricing over generic naftifine.
• Continued physician preference for the branded vehicle.
• Exclusive distribution or specialty-pharmacy access.
• A differentiated formulation with limited substitution.
• A formulation patent that delays generic entry.

For a generic entrant, the strongest business case is usually a low-cost, manufacturable formulation with reliable supply. For a specialty dermatology company, the stronger opportunity is a new delivery system that supports a distinct FDA label and a defensible patent position.

Key takeaways

• Naftin is a mature topical naftifine hydrochloride product with no biosimilar pathway.
• The 1% gel and 2% cream use conventional excipient systems that can be improved for sensory performance and tolerability.
• Broad molecule-based exclusivity is not the primary commercial barrier.
• The best formulation opportunities are low-irritation gel, elegant cream, foam or spray delivery, and nail-targeted systems.
• A simple generic is likely to face price competition and limited differentiation.
• A novel delivery system may require a 505(b)(2) application rather than a conventional ANDA.
• Current Orange Book listings and litigation must be checked by NDA, dosage form, and strength before making a launch or freedom-to-operate decision.
• Stronger patent positions will depend on unexpected formulation results, not routine substitution of excipients.
• Manufacturing complexity is manageable for creams and gels but rises sharply for foams, films, sprays, and nail products.
• The best licensing opportunities are reusable topical-delivery platforms rather than rights to legacy naftifine chemistry.

FAQs about Naftin excipient and formulation opportunities

Can a generic Naftin product use different excipients?

Yes, but excipient differences must not alter product performance, local exposure, stability, safety, or other FDA requirements. The regulatory burden depends on the extent of the formulation change and the applicable product-specific guidance.

Is Naftin suitable for a foam formulation?

Naftifine may be technically adaptable to a foam, but solvent selection, drug solubility, dose uniformity, propellant compatibility, flammability, and local tolerance would require dedicated development and regulatory testing.

Could a preservative-free Naftin cream obtain premium pricing?

Potentially, but premium pricing would require a meaningful patient or prescriber benefit, reliable microbiological control, suitable packaging, and evidence that the product improves tolerability or adherence.

Is a Naftin nail product likely to be a standard generic?

Usually not. A nail-targeted system would likely differ materially from a conventional skin cream or gel and could require a 505(b)(2) pathway with new performance or clinical evidence.

What is the most commercially attractive Naftin formulation?

The most practical opportunity is an alcohol-reduced, low-residue gel or a cosmetically improved cream. Foam, spray, and nail systems offer greater differentiation but carry higher development, regulatory, and manufacturing risk.

References

1. DailyMed. (n.d.). Naftin: Naftifine hydrochloride gel, 1% prescribing information. U.S. National Library of Medicine.
2. DailyMed. (n.d.). Naftin: Naftifine hydrochloride cream, 2% prescribing information. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2022). Product-specific guidances for generic drug development: Topical dermatological products.
5. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications.